LXF 821
Alternative Names: EGFR CAR-T; LXF-821Latest Information Update: 28 Sep 2024
At a glance
- Originator Novartis
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glioblastoma
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Glioblastoma in Switzerland (Parenteral)
- 12 Aug 2021 Phase-I clinical trials in Glioblastoma in Switzerland (Parenteral) before August 2021
- 11 Aug 2021 Early research in Glioblastoma in Switzerland (Parenteral) before August 2021